S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)
Philip A. Philip, Paul E. Oberstein, Zev A. Wainberg, E. Gabriela Chiorean et al.
Citations
2 citations
Journal
Future Oncology
Topics
Gastric Cancer Management and Outcomes
Field-Weighted Citation Impact (FWCI)
3.04
article
S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)
Philip A. Philip, Paul E. Oberstein, Zev A. Wainberg, E. Gabriela Chiorean, Colmar Figueroa-Moseley, Dan G. Duda, Flavio G. Rocha, Maheswari Senthil, Katherine A. Guthrie, Anwaar Saeed, Rachael A. Safyan, Robin Park, Sarah Colby, Syma Iqbal, Riha Vaidya, Rajiv Agarwal, Joseph M. Unger
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Future OncologyVol. 21(11)
Institutions
University of Southern California (US), Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA), Oregon Health & Science University (US), Wayne State University (US), Breast Cancer Research Foundation (US), Vanderbilt University (US), University of Washington (US), University of California, Irvine (US), Henry Ford Hospital (US), Moffitt Cancer Center (US), NYU Langone Health (US), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), USC Norris Comprehensive Cancer Center (US), UPMC Hillman Cancer Center (US), Vanderbilt-Ingram Cancer Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, UC Davis Comprehensive Cancer Center, University of California, Davis (US)
Funders
National Institutes of Health, National Cancer Institute